Tuesday, 17 November 2026 Every SEC filing alert, by company
ALFA USA Filings Every alert, straight from SEC EDGAR
News

CytomX Therapeutics, Inc.

NASDAQ: CTMX · Life Sciences · 1 alert · CIK 1501989

Share price
$1.99Close, Nov 16
Market cap
$433M
Shares outstanding
218MLatest SEC cover page
Sector
Life Sciences
Industry
Pharmaceutical PreparationsSIC 2834

Today's reference numbers: shares from the company's latest SEC cover page, price from the latest market close. Not a valuation or a recommendation. All CytomX Therapeutics, Inc. filings on SEC EDGAR ↗

4:11 PM ET 8-K
Financial Results

CytomX Therapeutics Financial Results

CytomX Therapeutics reported Q3 2026 financial results and provided a business update, highlighting that its lead candidate Varsetatug masetecan (Varseta-M) received FDA Fast Track designation for metastatic colorectal cancer. The company expects to provide a Phase 1 monotherapy data update in January 2027 and potentially initiate its first registrational study in the first half of 2027.

“Varseta-M is a first-in-class EpCAM-directed antibody drug conjugate with a topoisomerase-1 inhibitor payload, intentionally designed to improve the standard of care for patients with colorectal and other cancers. At CytomX, we are highly focused on rapidly advancing monotherapy Varseta-M towards a first registrational study in colorectal cancer.”

Dr. Sean McCarthy, chairman and CEO of CytomX Therapeutics

“Additionally, the Varseta-M development program continues to broaden, including an ongoing combination study with bevacizumab in mCRC and the initiation of Phase 1 expansion cohorts in gastric and gastroesophageal junction cancer, EpCAM-selected pancreatic ductal adenocarcinoma, and EpCAM-selected biliary tract cancer. Our integrated strategy is intended to urgently advance Varseta-M for the maximum benefit of cancer patients.”

Dr. Sean McCarthy, chairman and CEO of CytomX Therapeutics

Get Alerts

Get ALFA Finder alerts first

Real-time SEC filing alerts for US stocks are launching soon. Leave your details and we'll tell you the moment they go live.